sor Eric Morand, principal investigator. “These studies are designed to further explore how targeting shared inflammatory pathways may benefit patients across the lupus spectrum.”

Lupus is a chronic autoimmune disease that can affect multiple organ systems, including the skin, joints, kidneys and central nervous system.2Up to 85% of patients experience skin manifestations, which are among the most visible signs of disease and may reflect underlying immune-driven inflammation.1

Skin manifestations can be life-altering and sometimes are irreversible on their own.3,4They can present as inflamed, photosensitive lesions on the face, scalp and other areas, and may lead to scarring or pigment changes.5Despite their prevalence and the fact that skin manifestations are the first sign of disease in nearly one third (29%) of cases,1many patients still do not achieve adequate disease control.6

“Skin symptoms impose a profound and multilayered burden
=*=*=*=*=*=
当前为第3/10页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页